vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and SIMMONS FIRST NATIONAL CORP (SFNC). Click either name above to swap in a different company.
SIMMONS FIRST NATIONAL CORP is the larger business by last-quarter revenue ($197.3M vs $139.2M, roughly 1.4× ADMA BIOLOGICS, INC.). On growth, SIMMONS FIRST NATIONAL CORP posted the faster year-over-year revenue change (19.6% vs 18.4%). SIMMONS FIRST NATIONAL CORP produced more free cash flow last quarter ($411.4M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 0.6%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Simmons Bank is a bank with operations in Arkansas, Kansas, Missouri, Oklahoma, Tennessee, and Texas. It is the primary subsidiary of Simmons First National Corporation, a bank holding company.
ADMA vs SFNC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $197.3M |
| Net Profit | $49.4M | — |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | — |
| Net Margin | 35.5% | — |
| Revenue YoY | 18.4% | 19.6% |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $197.3M | ||
| Q3 25 | $134.2M | $186.7M | ||
| Q2 25 | $122.0M | $214.2M | ||
| Q1 25 | $114.8M | $209.6M | ||
| Q4 24 | $117.5M | $208.5M | ||
| Q3 24 | $119.8M | $174.8M | ||
| Q2 24 | $107.2M | $197.2M | ||
| Q1 24 | $81.9M | $195.1M |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $-562.8M | ||
| Q2 25 | $34.2M | $54.8M | ||
| Q1 25 | $26.9M | $32.4M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $24.7M | ||
| Q2 24 | $32.1M | $40.8M | ||
| Q1 24 | $17.8M | $38.9M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | — | ||
| Q3 25 | 38.0% | — | ||
| Q2 25 | 35.1% | — | ||
| Q1 25 | 30.4% | — | ||
| Q4 24 | 32.6% | — | ||
| Q3 24 | 33.1% | — | ||
| Q2 24 | 36.6% | — | ||
| Q1 24 | 26.7% | — |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | -301.5% | ||
| Q2 25 | 28.1% | 25.6% | ||
| Q1 25 | 23.4% | 15.5% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | 14.1% | ||
| Q2 24 | 29.9% | 20.7% | ||
| Q1 24 | 21.7% | 19.9% |
| Q4 25 | $0.20 | $0.36 | ||
| Q3 25 | $0.15 | $-4.00 | ||
| Q2 25 | $0.14 | $0.43 | ||
| Q1 25 | $0.11 | $0.26 | ||
| Q4 24 | $0.45 | $0.38 | ||
| Q3 24 | $0.15 | $0.20 | ||
| Q2 24 | $0.13 | $0.32 | ||
| Q1 24 | $0.08 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | $620.0M |
| Stockholders' EquityBook value | $477.3M | $3.4B |
| Total Assets | $624.2M | $24.5B |
| Debt / EquityLower = less leverage | 0.15× | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | — | ||
| Q1 24 | $45.3M | — |
| Q4 25 | $72.1M | $620.0M | ||
| Q3 25 | $72.4M | $667.8M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | $72.3M | $1.1B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $477.3M | $3.4B | ||
| Q3 25 | $431.2M | $3.4B | ||
| Q2 25 | $398.3M | $3.5B | ||
| Q1 25 | $373.4M | $3.5B | ||
| Q4 24 | $349.0M | $3.5B | ||
| Q3 24 | $231.9M | $3.5B | ||
| Q2 24 | $188.3M | $3.5B | ||
| Q1 24 | $153.7M | $3.4B |
| Q4 25 | $624.2M | $24.5B | ||
| Q3 25 | $568.7M | $24.2B | ||
| Q2 25 | $558.4M | $26.7B | ||
| Q1 25 | $510.6M | $26.8B | ||
| Q4 24 | $488.7M | $26.9B | ||
| Q3 24 | $390.6M | $27.3B | ||
| Q2 24 | $376.4M | $27.4B | ||
| Q1 24 | $350.9M | $27.4B |
| Q4 25 | 0.15× | 0.18× | ||
| Q3 25 | 0.17× | 0.20× | ||
| Q2 25 | — | 0.28× | ||
| Q1 25 | — | 0.35× | ||
| Q4 24 | 0.21× | 0.32× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $449.5M |
| Free Cash FlowOCF − Capex | $34.6M | $411.4M |
| FCF MarginFCF / Revenue | 24.8% | 208.5% |
| Capex IntensityCapex / Revenue | 0.8% | 19.3% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $717.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $449.5M | ||
| Q3 25 | $13.3M | $223.4M | ||
| Q2 25 | $21.1M | $77.6M | ||
| Q1 25 | $-19.7M | $32.8M | ||
| Q4 24 | $50.2M | $425.9M | ||
| Q3 24 | $25.0M | $199.4M | ||
| Q2 24 | $45.6M | $86.1M | ||
| Q1 24 | $-2.2M | $57.6M |
| Q4 25 | $34.6M | $411.4M | ||
| Q3 25 | $-1.1M | $216.7M | ||
| Q2 25 | $18.7M | $66.3M | ||
| Q1 25 | $-24.4M | $22.6M | ||
| Q4 24 | $47.5M | $380.4M | ||
| Q3 24 | $24.0M | $187.7M | ||
| Q2 24 | $43.6M | $72.7M | ||
| Q1 24 | $-4.6M | $47.7M |
| Q4 25 | 24.8% | 208.5% | ||
| Q3 25 | -0.8% | 116.1% | ||
| Q2 25 | 15.3% | 31.0% | ||
| Q1 25 | -21.2% | 10.8% | ||
| Q4 24 | 40.4% | 182.5% | ||
| Q3 24 | 20.0% | 107.4% | ||
| Q2 24 | 40.7% | 36.9% | ||
| Q1 24 | -5.6% | 24.5% |
| Q4 25 | 0.8% | 19.3% | ||
| Q3 25 | 10.7% | 3.6% | ||
| Q2 25 | 2.0% | 5.3% | ||
| Q1 25 | 4.1% | 4.8% | ||
| Q4 24 | 2.3% | 21.8% | ||
| Q3 24 | 0.9% | 6.7% | ||
| Q2 24 | 1.9% | 6.8% | ||
| Q1 24 | 2.9% | 5.0% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | 1.42× | ||
| Q1 25 | -0.73× | 1.01× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 8.06× | ||
| Q2 24 | 1.42× | 2.11× | ||
| Q1 24 | -0.12× | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
SFNC
Segment breakdown not available.
